Robert Chase
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert Chase has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Jeong Hyun Yun
Channing Division of Network Medicine, Brigham and Women’s Hospital, Boston, USA
4 shared publications - Peter J. Castaldi
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02215, USA
4 shared publications - Craig P. Hersh
Channing Division of Network Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA, 02115, USA.
3 shared publications Leanna Farnam
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
3 shared publicationsZhonghui Xu
Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA
3 shared publications- Aabida Saferali
Brigham and Women's Hospital
2 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Joint clinical and molecular subtyping of COPD with variational autoencoders
Chronic Obstructive Pulmonary Disease (COPD) is a complex, heterogeneous disease. Traditional subtyping methods generally focus on either the clinical manifestations or the molecular endotypes of the disease, leading to classifications that only partially reflect disease heterogeneity. Here, we introduce a variational autoencoder-based subtyping pipeline that jointly embeds clinical and gene expression data into a single subject-level representation. We evaluate the framework in the COPDGene study, a large study of current and former smoking individuals with and without COPD. Prediction experiments show that the embeddings have predictive accuracy comparable to or better than other unsupervised embedding approaches. Using trajectory learning approaches, we identify five well-separated subtypes with distinct clinical phenotypes, expression signatures, and longitudinal outcomes. Finally, we show that our findings generalize to an external validation cohort. Overall, our approach enables a transition from isolated phenotypic or molecular subtyping toward an integrated and clinically meaningful understanding of COPD heterogeneity.
- 19 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessJoint clinical and molecular subtyping of COPD with variational autoencoders
Chronic Obstructive Pulmonary Disease (COPD) is a complex, heterogeneous disease. Traditional subtyping methods generally focus on either the clinical manifestations or the molecular endotypes of the disease, leading to classifications that only partially reflect disease heterogeneity. Here, we introduce a variational autoencoder-based subtyping pipeline that jointly embeds clinical and gene expression data into a single subject-level representation. We evaluate the framework in the COPDGene study, a large study of current and former smoking individuals with and without COPD. Prediction experiments show that the embeddings have predictive accuracy comparable to or better than other unsupervised embedding approaches. Using trajectory learning approaches, we identify five well-separated subtypes with distinct clinical phenotypes, expression signatures, and longitudinal outcomes. Finally, we show that our findings generalize to an external validation cohort. Overall, our approach enables a transition from isolated phenotypic or molecular subtyping toward an integrated and clinically meaningful understanding of COPD heterogeneity.
- Open Access
- 2 February 2023
- Published by F1000 Research Ltd in F1000Research
- Vol. 12, 123
Blood RNA and protein biomarkers are associated with vaping and dual use, and prospective health outcomes
Background:Electronic nicotine delivery systems (ENDS) are driving an epidemic of vaping. Identifying biomarkers of vaping and dual use (concurrent vaping and smoking) will facilitate studies of the health effects of vaping. To identify putative biomarkers of vaping and dual use, we performed association analysis in an observational cohort of 3,892 COPDGene study participants with blood transcriptomics and/or plasma proteomics data and self-reported current vaping and smoking behavior. Methods:Biomarkers of vaping and dual use were identified through differential expression analysis and related to prospective health events over six years of follow-up. To assess the predictive accuracy of multi-biomarker panels, we constructed predictive models for vaping and smoking categories and prospective health outcomes. Results:We identified three transcriptomic and three proteomic associations with vaping, and 90 transcriptomic and 100 proteomic associations to dual use. Many of these vaping or dual use biomarkers were significantly associated with prospective health outcomes, such as FEV1 decline (three transcripts and 62 proteins), overall mortality (18 transcripts and 73 proteins), respiratory mortality (two transcripts and 23 proteins), respiratory exacerbations (13 proteins) and incident cardiovascular disease (24 proteins). Multimarker models showed good performance discriminating between vaping and smoking behavior and produced informative, modestly powerful predictions of future FEV1 decline, mortality, and respiratory exacerbations. Conclusions:In summary, vaping and dual use are associated with RNA and protein blood-based biomarkers that are also associated with adverse health outcomes.
- 2 February 2023
- Published by F1000 Research Ltd in F1000Research
- Vol. 12, 123
Open AccessBlood RNA and protein biomarkers are associated with vaping and dual use, and prospective health outcomes
Background:Electronic nicotine delivery systems (ENDS) are driving an epidemic of vaping. Identifying biomarkers of vaping and dual use (concurrent vaping and smoking) will facilitate studies of the health effects of vaping. To identify putative biomarkers of vaping and dual use, we performed association analysis in an observational cohort of 3,892 COPDGene study participants with blood transcriptomics and/or plasma proteomics data and self-reported current vaping and smoking behavior. Methods:Biomarkers of vaping and dual use were identified through differential expression analysis and related to prospective health events over six years of follow-up. To assess the predictive accuracy of multi-biomarker panels, we constructed predictive models for vaping and smoking categories and prospective health outcomes. Results:We identified three transcriptomic and three proteomic associations with vaping, and 90 transcriptomic and 100 proteomic associations to dual use. Many of these vaping or dual use biomarkers were significantly associated with prospective health outcomes, such as FEV1 decline (three transcripts and 62 proteins), overall mortality (18 transcripts and 73 proteins), respiratory mortality (two transcripts and 23 proteins), respiratory exacerbations (13 proteins) and incident cardiovascular disease (24 proteins). Multimarker models showed good performance discriminating between vaping and smoking behavior and produced informative, modestly powerful predictions of future FEV1 decline, mortality, and respiratory exacerbations. Conclusions:In summary, vaping and dual use are associated with RNA and protein blood-based biomarkers that are also associated with adverse health outcomes.
- 19 May 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 59 (5) , 2100569
An interferon-inducible signature of airway disease from blood gene expression profiling
Background: The molecular basis of airway remodelling in chronic obstructive pulmonary disease (COPD) remains poorly understood. We identified gene expression signatures associated with chest computed tomography (CT) scan airway measures to understand molecular pathways associated with airway disease.Methods: In 2396 subjects in the COPDGene Study, we examined the relationship between quantitative CT airway phenotypes and blood transcriptomes to identify airway disease-specific genes and to define an airway wall thickness (AWT) gene set score. Multivariable regression analyses were performed to identify associations of the AWT score with clinical phenotypes, bronchial gene expression and genetic variants.Results: Type 1 interferon (IFN)-induced genes were consistently associated with AWT, square root wall area of a hypothetical airway with 10 mm internal perimeter (Pi10) and wall area percentage, with the strongest enrichment in AWT. A score derived from 18 genes whose expression was associated with AWT was associated with COPD-related phenotypes including reduced lung function (forced expiratory volume in 1 s percentage predicted β= −3.4; pIKZF1, a gene that regulates IFN signalling and is associated with inflammatory diseases.Conclusions: A gene expression signature with IFN-stimulated genes from peripheral blood and bronchial brushings is associated with CT AWT, lung function and exacerbations. Shared genes and genetic associations suggest viral responses and/or autoimmune dysregulation as potential underlying mechanisms of airway disease in COPD.
- 19 May 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 59 (5) , 2100569
An interferon-inducible signature of airway disease from blood gene expression profiling
Background: The molecular basis of airway remodelling in chronic obstructive pulmonary disease (COPD) remains poorly understood. We identified gene expression signatures associated with chest computed tomography (CT) scan airway measures to understand molecular pathways associated with airway disease.Methods: In 2396 subjects in the COPDGene Study, we examined the relationship between quantitative CT airway phenotypes and blood transcriptomes to identify airway disease-specific genes and to define an airway wall thickness (AWT) gene set score. Multivariable regression analyses were performed to identify associations of the AWT score with clinical phenotypes, bronchial gene expression and genetic variants.Results: Type 1 interferon (IFN)-induced genes were consistently associated with AWT, square root wall area of a hypothetical airway with 10 mm internal perimeter (Pi10) and wall area percentage, with the strongest enrichment in AWT. A score derived from 18 genes whose expression was associated with AWT was associated with COPD-related phenotypes including reduced lung function (forced expiratory volume in 1 s percentage predicted β= −3.4; pIKZF1, a gene that regulates IFN signalling and is associated with inflammatory diseases.Conclusions: A gene expression signature with IFN-stimulated genes from peripheral blood and bronchial brushings is associated with CT AWT, lung function and exacerbations. Shared genes and genetic associations suggest viral responses and/or autoimmune dysregulation as potential underlying mechanisms of airway disease in COPD.
- 2 May 2022
- Published by Oxford University Press (OUP)
- p. A3268
Prediction of Electronic Nicotine Delivery Systems Use in COPDGene Using Multi-Omic Biomarkers
- 2 May 2022
- Published by Oxford University Press (OUP)
- p. A3268
Prediction of Electronic Nicotine Delivery Systems Use in COPDGene Using Multi-Omic Biomarkers
- Open Access
- 13 September 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (2) , e619-e630
Early Changes in Immune Cell Count, Metabolism, and Function Following Sleeve Gastrectomy: A Prospective Human Study
Objective: To characterize longitudinal changes in blood biomarkers, leukocyte composition, and gene expression following laparoscopic sleeve gastrectomy (LSG). Background: LSG is an effective treatment for obesity, leading to sustainable weight loss and improvements in obesity-related comorbidities and inflammatory profiles. However, the effects of LSG on immune function and metabolism remain uncertain. Methods: Prospective data were collected from 23 enrolled human subjects from a single institution. Parameters of weight, comorbidities, and trends in blood biomarkers and leukocyte subsets were observed from preoperative baseline to 1 year postsurgery in 3-month follow-up intervals. RNA sequencing was performed on pairs of whole blood samples from the first 6 subjects of the study (baseline and 3 months postsurgery) to identify genome-wide gene expression changes associated with undergoing LSG. Results: LSG led to a significant decrease in mean total body weight loss (18.1%) at 3 months and among diabetic subjects a reduction in hemoglobin A1c. Improvements in clinical inflammatory and hormonal biomarkers were demonstrated as early as 3 months after LSG. A reduction in neutrophil-lymphocyte ratio was observed, driven by a reduction in absolute neutrophil counts. Gene set enrichment analyses of differential whole blood gene expression demonstrated that after 3 months LSG induced transcriptomic changes not only in inflammatory cytokine pathways but also in several key metabolic pathways related to energy metabolism. Conclusions: LSG induces significant changes in the composition and metabolism of immune cells as early as 3 months postoperatively. Further evaluation is required of bariatric surgery’s effects on immunometabolism and the consequences for host defense and metabolic disease.
- 13 September 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (2) , e619-e630
Open AccessEarly Changes in Immune Cell Count, Metabolism, and Function Following Sleeve Gastrectomy: A Prospective Human Study
Objective: To characterize longitudinal changes in blood biomarkers, leukocyte composition, and gene expression following laparoscopic sleeve gastrectomy (LSG). Background: LSG is an effective treatment for obesity, leading to sustainable weight loss and improvements in obesity-related comorbidities and inflammatory profiles. However, the effects of LSG on immune function and metabolism remain uncertain. Methods: Prospective data were collected from 23 enrolled human subjects from a single institution. Parameters of weight, comorbidities, and trends in blood biomarkers and leukocyte subsets were observed from preoperative baseline to 1 year postsurgery in 3-month follow-up intervals. RNA sequencing was performed on pairs of whole blood samples from the first 6 subjects of the study (baseline and 3 months postsurgery) to identify genome-wide gene expression changes associated with undergoing LSG. Results: LSG led to a significant decrease in mean total body weight loss (18.1%) at 3 months and among diabetic subjects a reduction in hemoglobin A1c. Improvements in clinical inflammatory and hormonal biomarkers were demonstrated as early as 3 months after LSG. A reduction in neutrophil-lymphocyte ratio was observed, driven by a reduction in absolute neutrophil counts. Gene set enrichment analyses of differential whole blood gene expression demonstrated that after 3 months LSG induced transcriptomic changes not only in inflammatory cytokine pathways but also in several key metabolic pathways related to energy metabolism. Conclusions: LSG induces significant changes in the composition and metabolism of immune cells as early as 3 months postoperatively. Further evaluation is required of bariatric surgery’s effects on immunometabolism and the consequences for host defense and metabolic disease.
- Open Access
- 23 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (30)
Genomic signatures of the unjamming transition in compressed human bronchial epithelial cells
Temporal RNA-seq data reveal genomic signatures of the unjamming transition in compressed human bronchial epithelial cells.
- 23 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (30)
Open AccessGenomic signatures of the unjamming transition in compressed human bronchial epithelial cells
Temporal RNA-seq data reveal genomic signatures of the unjamming transition in compressed human bronchial epithelial cells.
- 1 June 2021
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (6) , 671-682
Commercially Available Blocking Oligonucleotides Effectively Suppress Unwanted Hemolysis-Related miRNAs in a Large Whole-Blood RNA Cohort
- 1 June 2021
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 23 (6) , 671-682
Commercially Available Blocking Oligonucleotides Effectively Suppress Unwanted Hemolysis-Related miRNAs in a Large Whole-Blood RNA Cohort
- Open Access
Early changes in immune cell metabolism and function are a hallmark of sleeve gastrectomy: a prospective human study
Objective To characterize longitudinal changes in blood biomarkers, leukocyte composition, and gene expression following laparoscopic sleeve gastrectomy (LSG). Background LSG is an effective treatment for obesity, leading to sustainable weight loss and improvements in obesity-related co-morbidities and inflammatory profiles. However, the effects of LSG on immune function and metabolism remain uncertain. Methods Prospective data was collected from 23 enrolled human subjects from a single institution. Parameters of weight, co-morbidities, and trends in blood biomarkers and leukocyte subsets were observed from pre-operative baseline to one year in three-month follow-up intervals. RNA-sequencing was performed on pairs of whole blood samples from the first six subjects of the study (baseline and three months post-surgery) to identify genome-wide gene expression changes associated with undergoing LSG. Results LSG led to a significant decrease in mean total body weight loss (18.1%) at three months and among diabetic subjects a reduction in HbA1c. Improvements in clinical inflammatory and hormonal biomarkers were demonstrated as early as three months after LSG. A reduction in neutrophil-lymphocyte ratio was observed, driven by a reduction in absolute neutrophil counts. Gene set enrichment analyses of differential whole blood gene expression demonstrated that after three months, LSG induced transcriptomic changes not only in inflammatory cytokine pathways but also in several key metabolic pathways related to energy metabolism. Conclusions LSG induces significant changes in the composition and metabolism of immune cells as early as three months post-operatively. Further evaluation is required of bariatric surgery's effects on immunometabolism and consequences for host defense and metabolic disease.
Open AccessEarly changes in immune cell metabolism and function are a hallmark of sleeve gastrectomy: a prospective human study
Objective To characterize longitudinal changes in blood biomarkers, leukocyte composition, and gene expression following laparoscopic sleeve gastrectomy (LSG). Background LSG is an effective treatment for obesity, leading to sustainable weight loss and improvements in obesity-related co-morbidities and inflammatory profiles. However, the effects of LSG on immune function and metabolism remain uncertain. Methods Prospective data was collected from 23 enrolled human subjects from a single institution. Parameters of weight, co-morbidities, and trends in blood biomarkers and leukocyte subsets were observed from pre-operative baseline to one year in three-month follow-up intervals. RNA-sequencing was performed on pairs of whole blood samples from the first six subjects of the study (baseline and three months post-surgery) to identify genome-wide gene expression changes associated with undergoing LSG. Results LSG led to a significant decrease in mean total body weight loss (18.1%) at three months and among diabetic subjects a reduction in HbA1c. Improvements in clinical inflammatory and hormonal biomarkers were demonstrated as early as three months after LSG. A reduction in neutrophil-lymphocyte ratio was observed, driven by a reduction in absolute neutrophil counts. Gene set enrichment analyses of differential whole blood gene expression demonstrated that after three months, LSG induced transcriptomic changes not only in inflammatory cytokine pathways but also in several key metabolic pathways related to energy metabolism. Conclusions LSG induces significant changes in the composition and metabolism of immune cells as early as three months post-operatively. Further evaluation is required of bariatric surgery's effects on immunometabolism and consequences for host defense and metabolic disease.
- Open Access
- 1 May 2020
- Published by Oxford University Press (OUP)
- p. A4467
An Interferon Inducible Signature of Airway Disease from Gene Expression Profiling of Peripheral Blood from COPDGene
- 1 May 2020
- Published by Oxford University Press (OUP)
- p. A4467
Open AccessAn Interferon Inducible Signature of Airway Disease from Gene Expression Profiling of Peripheral Blood from COPDGene